section name header

Pronunciation ⬇

a-mee-noe-ka-PRO-ik A-sid

Classifications ⬆ ⬇

Therapeutic Classification: hemostatic agents

Pharmacologic Classification: fibrinolysis inhibitors

Indications ⬆ ⬇

REMS


Unlabeled Use:
  • Prevention of recurrent subarachnoid hemorrhage.
  • Prevention of bleeding following oral surgery in hemophiliacs.
  • Management of severe hemorrhage caused by thrombolytic agents.

Action ⬆ ⬇

  • Inhibits activation of plasminogen.
Therapeutic effects:
  • Inhibition of fibrinolysis.
  • Stabilization of clot formation.

Pharmacokinetics ⬆ ⬇

Absorption: Rapidly absorbed following oral administration.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Mostly eliminated unchanged by the kidneys.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2 hrN/A
IVunknown2 hrN/A



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: arrhythmias, hypotension (IV only)

EENT: nasal stuffiness, tinnitus

GI: anorexia, bloating, cramping, diarrhea, nausea

GU: diuresis, renal failure

MS: myopathy

Neuro: dizziness, malaise

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Acute Bleeding Syndromes due to Elevated Fibrinolytic Activity

Subarachnoid Hemorrhage

Prevention of Bleeding Following Oral Surgery in Hemophiliacs

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Amicar